| Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? SHI Ou, M Nagasaka, D Brazel, Y Hou, VW Zhu Translational oncology 14 (11), 101191, 2021 | 40 | 2021 |
| Spotlight on amivantamab (JNJ-61186372) for EGFR exon 20 insertions positive non-small cell lung cancer D Brazel, M Nagasaka Lung Cancer: Targets and Therapy, 133-138, 2021 | 27 | 2021 |
| Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options D Brazel, G Kroening, M Nagasaka BioDrugs 36 (6), 717-729, 2022 | 22 | 2022 |
| Tiragolumab (Anti-TIGIT) in SCLC: skyscraper-02, a towering inferno D Brazel, SHI Ou, M Nagasaka Lung Cancer: Targets and Therapy, 1-9, 2023 | 21 | 2023 |
| Spotlight on tepotinib and capmatinib for non-small cell lung cancer with MET exon 14 skipping mutation D Brazel, S Zhang, M Nagasaka Lung Cancer: Targets and Therapy, 33-45, 2022 | 16 | 2022 |
| Rash and Mucositis Associated With Mycoplasma pneumoniae and Chlamydophila pneumoniae: A Recurrence of MIRM? D Brazel, B Kulp, G Bautista, A Bonwit Journal of the Pediatric Infectious Diseases Society 10 (2), 220-224, 2021 | 16 | 2021 |
| The cure from within? a review of the microbiome and diet in melanoma P Kumar, D Brazel, J DeRogatis, JBG Valerin, K Whiteson, WA Chow, ... Cancer and Metastasis Reviews 41 (2), 261-280, 2022 | 14 | 2022 |
| Genomic alterations and tumor mutation burden in Merkel cell carcinoma D Brazel, P Kumar, H Doan, T Pan, W Shen, L Gao, JT Moyers JAMA Network Open 6 (1), e2249674-e2249674, 2023 | 13 | 2023 |
| The development of amivantamab for the treatment of non-small cell lung cancer D Brazel, M Nagasaka Respiratory Research 24 (1), 256, 2023 | 12 | 2023 |
| Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset M Nagasaka, D Brazel, Y Baca, J Xiu, MN Al-Hallak, C Kim, J Nieva, ... Translational Oncology 36, 101744, 2023 | 11 | 2023 |
| Eponyms in medical oncology P Kumar, D Brazel, DJ Benjamin, E Brem Cancer treatment and research communications 31, 100516, 2022 | 11 | 2022 |
| Stroke in sickle cell disease and the promise of recent disease modifying agents A Runge, D Brazel, Z Pakbaz Journal of the Neurological Sciences 442, 120412, 2022 | 10 | 2022 |
| A long overdue targeted treatment for KRAS mutations in NSCLC: Spotlight on Adagrasib D Brazel, Z Arter, M Nagasaka Lung Cancer: Targets and Therapy, 75-80, 2022 | 10 | 2022 |
| Physical activity and central adiposity in a cohort of African-American adults S McGrath, D Brazel, L Dugas, G Cao, R Durazo-Arvizu, A Luke BMC obesity 4, 1-9, 2017 | 10 | 2017 |
| MARIPOSA: Can amivantamab and lazertinib replace osimertinib in the front-line setting? D Brazel, M Nagasaka Lung Cancer: Targets and Therapy, 41-47, 2024 | 9 | 2024 |
| Warm and cold autoimmune hemolytic anemia in the setting of COVID-19 disease D Brazel, T Eid, C Harding Cureus 13 (9), 2021 | 8 | 2021 |
| Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies S Zhang, D Brazel, P Kumar, LN Schafer, B Eidenschink, M Senthil, ... Journal of Gastrointestinal Oncology 12 (6), 2643, 2021 | 7 | 2021 |
| Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC D Brazel, M Nagasaka Targeted Oncology 19 (3), 297-301, 2024 | 4 | 2024 |
| The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and … D Brazel, SI Ou Lung Cancer: Targets and Therapy, 63-69, 2023 | 4 | 2023 |
| Multiorgan failure from nivolumab and ipilimumab: A case report and literature review D Brazel, S Lee, A Mahadevan, B Warnecke, R Parajuli Cureus 15 (7), 2023 | 4 | 2023 |